Evidence map›Paper›PMID 25950010›Full record

ArticleJournal of immunology research2015

TACI expression and signaling in chronic lymphocytic leukemia.

Antigoni Mamara, Anastasios E Germenis, Maria Kompoti, Maria Palassopoulou, Eudokia Mandala, Anastasia Banti, Nikolaos Giannakoulas, Matthaios Speletas

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of immunology research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Prognostic Significance of Serum BAFF, APRIL, TACI and BCMA Levels in Chronic Lymphocytic Leukemia.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2019
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Antigoni MamaraDepartment of Immunology & Histocompatibility, Faculty of Medicine, School of Health Sciences, University of Thessaly, Biopolis 3, 41500 Larissa, Greece.
Anastasios E GermenisDepartment of Immunology & Histocompatibility, Faculty of Medicine, School of Health Sciences, University of Thessaly, Biopolis 3, 41500 Larissa, Greece.
Maria KompotiDepartment of Immunology & Histocompatibility, Faculty of Medicine, School of Health Sciences, University of Thessaly, Biopolis 3, 41500 Larissa, Greece.
Maria PalassopoulouDepartment of Hematology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Biopolis 3, 41500 Larissa, Greece.
Eudokia MandalaFourth Department of Internal Medicine, Ippokration Hospital, Aristotle University of Thessaloniki, Konstantinoupoleos 49, 54642 Thessaloniki, Greece.
Anastasia BantiDepartment of Hematology, Papageorgiou General Hospital, Periferiaki Odos Thessalonikis, Nea Efkarpia, 56429 Thessaloniki, Greece.
Nikolaos GiannakoulasDepartment of Hematology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Biopolis 3, 41500 Larissa, Greece.
Matthaios SpeletasDepartment of Immunology & Histocompatibility, Faculty of Medicine, School of Health Sciences, University of Thessaly, Biopolis 3, 41500 Larissa, Greece.ORCID 0000-0003-1287-7734
University of Thessaly · GRAristotle University of Thessaloniki · GRPapageorgiou General Hospital · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

TACI is a membrane receptor of BAFF and APRIL, contributing to the differentiation and survival of normal B cells. Although malignant B cells are also subjected on TACI signaling, there is a remarkable intradisease and interindividual variability of TACI expression in B-cell malignancies. The aim of our study was to explore the possible role of TACI signaling in the biology of chronic lymphocytic leukemia (CLL), including its phenotypic and clinical characteristics and prognosis. Ninety-four patients and 19 healthy controls were studied. CLL patients exhibited variable TACI expression, with the majority of cases displaying low to undetectable TACI, along with low to undetectable BAFF and increased APRIL serum levels compared to healthy controls. CLL cells with high TACI expression displayed a better survival capacity in vitro, when cultured with BAFF and/or APRIL. Moreover, TACI expression was positively correlated with the presence of monoclonal gammopathy and inversely with CD11c expression. Therefore, our study provides further evidence for the contribution of BAFF/APRIL signaling to CLL biology, suggesting also that TACI detection might be useful in the selection of patients for novel targeting therapeutic approaches.

Indexed as

AdultAgedAged, 80 and overApoptosisB-Cell Activating FactorB-LymphocytesCD11c AntigenCell DifferentiationFemaleHumansImmunoglobulin AImmunoglobulin GImmunoglobulin MLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedB-Cell Activating FactorCD11c AntigenImmunoglobulin AImmunoglobulin GImmunoglobulin MRNA, MessengerTNFRSF13B protein, humanTNFSF13B protein, humanTNFSF13 protein, humanTransmembrane Activator and CAML Interactor ProteinTumor Necrosis Factor Ligand Superfamily Member 13

Identifiers

PMID25950010
PMCPMC4408744
OpenAlexW2030742917

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.